BACKGROUND: Pancreatic cancer is an aggressive cancer with a low survival time. So far, there have been no studies assessing direct and indirect costs in individual patients. AIM: To assess prospectively the cost of illness in patients with pancreatic cancer. METHODS: Patients were consecutively included at first admission to hospital. Sociodemographic factors, medical resource use and employment status were assessed by patient interviews and from medical records in a standardized way. Costs were calculated from the perspectives of the hospital, social insurance and society. Linear regression analyses were used to determine factors associated with costs. RESULTS: A total of 57 patients were admitted with suspected pancreatic cancer. Of these patients, 45 (79%) had pancreatic cancer as final diagnosis, 11 (19%) pancreatitis and one patient cystadenoma. The median survival was 10.9 months in patients with pancreatic cancer. Per month of observation from societal perspective, total costs were 4075 for patients. Costs of hospitalizations were responsible for 75% of total costs. In multivariable analyses, surgery, a lower educational level, younger age, and the prevalence of metastases were significantly associated with higher total costs. CONCLUSIONS: Costs are considerable in patients with pancreatic cancer. Our results may facilitate further economic evaluations and aid health policy-makers in resource allocation.
BACKGROUND:Pancreatic cancer is an aggressive cancer with a low survival time. So far, there have been no studies assessing direct and indirect costs in individual patients. AIM: To assess prospectively the cost of illness in patients with pancreatic cancer. METHODS:Patients were consecutively included at first admission to hospital. Sociodemographic factors, medical resource use and employment status were assessed by patient interviews and from medical records in a standardized way. Costs were calculated from the perspectives of the hospital, social insurance and society. Linear regression analyses were used to determine factors associated with costs. RESULTS: A total of 57 patients were admitted with suspected pancreatic cancer. Of these patients, 45 (79%) had pancreatic cancer as final diagnosis, 11 (19%) pancreatitis and one patientcystadenoma. The median survival was 10.9 months in patients with pancreatic cancer. Per month of observation from societal perspective, total costs were 4075 for patients. Costs of hospitalizations were responsible for 75% of total costs. In multivariable analyses, surgery, a lower educational level, younger age, and the prevalence of metastases were significantly associated with higher total costs. CONCLUSIONS: Costs are considerable in patients with pancreatic cancer. Our results may facilitate further economic evaluations and aid health policy-makers in resource allocation.
Authors: June S Peng; Jeffrey Mino; Rosebel Monteiro; Gareth Morris-Stiff; Noaman S Ali; Jane Wey; Kevin M El-Hayek; R Matthew Walsh; Sricharan Chalikonda Journal: J Gastrointest Surg Date: 2017-06-08 Impact factor: 3.452
Authors: Bobby Tingstedt; Erik Andersson; Anton Flink; Kristian Bolin; Björn Lindgren; Roland Andersson Journal: World J Surg Date: 2011-10 Impact factor: 3.352
Authors: Caitriona B O'Neill; Coral L Atoria; Eileen M O'Reilly; Jennifer LaFemina; Martin C Henman; Elena B Elkin Journal: Cancer Date: 2012-03-13 Impact factor: 6.860
Authors: Tina Stellwag; Christoph W Michalski; Bo Kong; Mert Erkan; Carolin Reiser-Erkan; Carsten Jäger; Christian Meinl; Helmut Friess; Jörg Kleeff Journal: Langenbecks Arch Surg Date: 2013-06-19 Impact factor: 3.445
Authors: Sophie Lauzier; Elizabeth Maunsell; Mélanie Drolet; Douglas Coyle; Nicole Hébert-Croteau Journal: Qual Life Res Date: 2010-01-22 Impact factor: 4.147
Authors: Jacqueline Müller-Nordhorn; Heike Englert; Karl Wegscheider; Hendrike Berger; Frank Sonntag; Heinz Völler; Wolfgang Meyer-Sabellek; Thomas Reinhold; Eberhard Windler; Hugo A Katus; Stefan N Willich Journal: Clin Res Cardiol Date: 2007-12-01 Impact factor: 5.460
Authors: A Carrato; A Falcone; M Ducreux; J W Valle; A Parnaby; K Djazouli; K Alnwick-Allu; A Hutchings; C Palaska; I Parthenaki Journal: J Gastrointest Cancer Date: 2015-09
Authors: Anthony Ssebagereka; Rebecca Racheal Apolot; Evelyne Baelvina Nyachwo; Elizabeth Ekirapa-Kiracho Journal: Int J Equity Health Date: 2021-01-02